The EMT Transcription Factor ZEB2 Promotes Proliferation of Primary and Metastatic Melanoma While Suppressing an Invasive, Mesenchymal-Like Phenotype.


Journal

Cancer research
ISSN: 1538-7445
Titre abrégé: Cancer Res
Pays: United States
ID NLM: 2984705R

Informations de publication

Date de publication:
15 07 2020
Historique:
received: 01 08 2019
revised: 02 03 2020
accepted: 18 05 2020
pubmed: 7 6 2020
medline: 24 11 2020
entrez: 7 6 2020
Statut: ppublish

Résumé

Epithelial-to-mesenchymal transition (EMT)-inducing transcription factors (TF) are well known for their ability to induce mesenchymal states associated with increased migratory and invasive properties. Unexpectedly, nuclear expression of the EMT-TF ZEB2 in human primary melanoma has been shown to correlate with reduced invasion. We report here that ZEB2 is required for outgrowth for primary melanomas and metastases at secondary sites. Ablation of

Identifiants

pubmed: 32503808
pii: 0008-5472.CAN-19-2373
doi: 10.1158/0008-5472.CAN-19-2373
doi:

Substances chimiques

Transcription Factors 0
Zinc Finger E-box Binding Homeobox 2 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2983-2995

Informations de copyright

©2020 American Association for Cancer Research.

Auteurs

Niels Vandamme (N)

Molecular and Cellular Oncology Laboratory, Department of Biomedical Molecular Biology, Ghent University, Ghent, Belgium.
Cancer Research Institute Ghent (CRIG), Ghent, Belgium.
VIB-UGent Center for Inflammation Research, Ghent, Belgium.

Geertrui Denecker (G)

Molecular and Cellular Oncology Laboratory, Department of Biomedical Molecular Biology, Ghent University, Ghent, Belgium.
Cancer Research Institute Ghent (CRIG), Ghent, Belgium.

Kenneth Bruneel (K)

Molecular and Cellular Oncology Laboratory, Department of Biomedical Molecular Biology, Ghent University, Ghent, Belgium.
Cancer Research Institute Ghent (CRIG), Ghent, Belgium.

Gillian Blancke (G)

Molecular and Cellular Oncology Laboratory, Department of Biomedical Molecular Biology, Ghent University, Ghent, Belgium.
Cancer Research Institute Ghent (CRIG), Ghent, Belgium.

Özden Akay (Ö)

Molecular and Cellular Oncology Laboratory, Department of Biomedical Molecular Biology, Ghent University, Ghent, Belgium.
Cancer Research Institute Ghent (CRIG), Ghent, Belgium.
VIB-UGent Center for Inflammation Research, Ghent, Belgium.
Laboratory for Molecular Cancer Biology, VIB Center for Cancer Biology, Leuven, Belgium.
Laboratory for Molecular Cancer Biology, Department of Oncology, KULeuven, Leuven, Belgium.

Joachim Taminau (J)

Molecular and Cellular Oncology Laboratory, Department of Biomedical Molecular Biology, Ghent University, Ghent, Belgium.
Cancer Research Institute Ghent (CRIG), Ghent, Belgium.

Jordy De Coninck (J)

Molecular and Cellular Oncology Laboratory, Department of Biomedical Molecular Biology, Ghent University, Ghent, Belgium.
Cancer Research Institute Ghent (CRIG), Ghent, Belgium.

Eva De Smedt (E)

Molecular and Cellular Oncology Laboratory, Department of Biomedical Molecular Biology, Ghent University, Ghent, Belgium.
Cancer Research Institute Ghent (CRIG), Ghent, Belgium.

Nicolas Skrypek (N)

Molecular and Cellular Oncology Laboratory, Department of Biomedical Molecular Biology, Ghent University, Ghent, Belgium.
Cancer Research Institute Ghent (CRIG), Ghent, Belgium.

Wouter Van Loocke (W)

Cancer Research Institute Ghent (CRIG), Ghent, Belgium.
Center for Medical Genetics, Department of Biomolecular Medicine, Ghent University and University Hospital, Ghent, Belgium.

Jasper Wouters (J)

Laboratory of Translational Cell and Tissue Research, Department of Pathology, KULeuven and UZ Leuven, Leuven, Belgium.

David Nittner (D)

Laboratory for Molecular Cancer Biology, VIB Center for Cancer Biology, Leuven, Belgium.
Laboratory for Molecular Cancer Biology, Department of Oncology, KULeuven, Leuven, Belgium.

Corinna Köhler (C)

Laboratory for Molecular Cancer Biology, VIB Center for Cancer Biology, Leuven, Belgium.
Laboratory for Molecular Cancer Biology, Department of Oncology, KULeuven, Leuven, Belgium.

Douglas S Darling (DS)

Department of Oral Immunology and Infectious Diseases, and Center for Genetics and Molecular Medicine, University of Louisville, Louisville, Kentucky.

Phil F Cheng (PF)

Department of Dermatology, University of Zurich, University of Zurich Hospital, Zurich, Switzerland.

Marieke I G Raaijmakers (MIG)

Department of Dermatology, University of Zurich, University of Zurich Hospital, Zurich, Switzerland.

Mitchell P Levesque (MP)

Department of Dermatology, University of Zurich, University of Zurich Hospital, Zurich, Switzerland.

Udupi Girish Mallya (UG)

Cancer Biology and Therapeutics Laboratory, UCD School of Biomolecular and Biomedical Science, UCD Conway Institute, University College, Dublin, Ireland.
OncoMark Limited, Nova UCD, Belfield Innovation Park, University College Dublin, Belfield, Dublin, Ireland.

Mairin Rafferty (M)

OncoMark Limited, Nova UCD, Belfield Innovation Park, University College Dublin, Belfield, Dublin, Ireland.

Balazs Balint (B)

OncoMark Limited, Nova UCD, Belfield Innovation Park, University College Dublin, Belfield, Dublin, Ireland.

William M Gallagher (WM)

Cancer Biology and Therapeutics Laboratory, UCD School of Biomolecular and Biomedical Science, UCD Conway Institute, University College, Dublin, Ireland.
OncoMark Limited, Nova UCD, Belfield Innovation Park, University College Dublin, Belfield, Dublin, Ireland.

Lieve Brochez (L)

Department of Head and Skin, Ghent University Hospital, Ghent, Belgium.

Danny Huylebroeck (D)

Department of Cell Biology, Erasmus University Medical Center, Rotterdam, the Netherlands.
Department of Development and Regeneration, KU Leuven, Leuven, Belgium.

Jody J Haigh (JJ)

Department of Pharmacology and Therapeutics, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada.
Research Institute in Oncology and Hematology, CancerCare Manitoba, Winnipeg, Manitoba, Canada.

Vanessa Andries (V)

Cancer Research Institute Ghent (CRIG), Ghent, Belgium.

Florian Rambow (F)

Laboratory for Molecular Cancer Biology, VIB Center for Cancer Biology, Leuven, Belgium.
Laboratory for Molecular Cancer Biology, Department of Oncology, KULeuven, Leuven, Belgium.

Pieter Van Vlierberghe (P)

Cancer Research Institute Ghent (CRIG), Ghent, Belgium.
Center for Medical Genetics, Department of Biomolecular Medicine, Ghent University and University Hospital, Ghent, Belgium.

Steven Goossens (S)

Molecular and Cellular Oncology Laboratory, Department of Biomedical Molecular Biology, Ghent University, Ghent, Belgium.
Cancer Research Institute Ghent (CRIG), Ghent, Belgium.
Center for Medical Genetics, Department of Biomolecular Medicine, Ghent University and University Hospital, Ghent, Belgium.

Joost J van den Oord (JJ)

Laboratory of Translational Cell and Tissue Research, Department of Pathology, KULeuven and UZ Leuven, Leuven, Belgium.

Jean-Christophe Marine (JC)

Laboratory for Molecular Cancer Biology, VIB Center for Cancer Biology, Leuven, Belgium.
Laboratory for Molecular Cancer Biology, Department of Oncology, KULeuven, Leuven, Belgium.

Geert Berx (G)

Molecular and Cellular Oncology Laboratory, Department of Biomedical Molecular Biology, Ghent University, Ghent, Belgium. geert.berx@ugent.be.
Cancer Research Institute Ghent (CRIG), Ghent, Belgium.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH